IVAN SPECTOR: Open Payments
NPI 1124207279 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,312 in 56 payments from 13 companies in 2025. Trend: 2023 $1,341 · 2024 $1,794 · 2025 $1,312
Food & beverage: $1,312
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $199 |
| Lundbeck LLC | 7 | $182 |
| Teva Pharmaceuticals USA, Inc. | 6 | $149 |
| ABBVIE INC. | 7 | $142 |
| Otsuka America Pharmaceutical, Inc. | 5 | $122 |
| Alkermes, Inc. | 4 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Neurocrine BioSciences, Inc. | 4 | $92 |
| E.R. Squibb & Sons, L.L.C. | 3 | $85 |
| Almatica Pharma LLC | 2 | $56 |
Products named: REXULTI, CAPLYTA, VRAYLAR, ARISTADA, TRINTELLIX, UZEDY, INGREZZA, COBENFY.
Industry payments across TX — which companies pay providers there.
